REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Perimeter Pharmaceuticals Llc Sp. z o.o. Oddzial W Polsce (Poland)

Main Activities: Pharmacies and Drug Stores
Secondary Activities: Other Direct Selling Establishments | Office Administrative Services | Telephone Call Centers | Packaging and Labeling Services | Convention and Trade Show Organizers | All Other Support Services
Full name: Perimeter Pharmaceuticals Llc Sp. z o.o. Oddzial W Polsce Profile Updated: May 26, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Perimeter Pharmaceuticals Llc Sp. z o.o. Oddzial W Polsce is based in Poland, with the head office in Atlanta. The company operates in the Pharmacies and Drug Stores sector. It was first established on November 10, 2017. A growth of 138.27% was recorded in its total assets.

Headquarters
Six Concourse Parkway
Atlanta; Stan Georgia Hrabstwo Fulton; Postal Code: 30-328

Contact Details: Purchase the Perimeter Pharmaceuticals Llc Sp. z o.o. Oddzial W Polsce report to view the information.

Website: http://adrespocztyelektronicznejoffice@perimeterpharmaceuticals.us

Basic Information
Outstanding Shares:
Purchase the Perimeter Pharmaceuticals Llc Sp. z o.o. Oddzial W Polsce report to view the information.
Incorporation Date:
November 10, 2017
Key Executives
Purchase this report to view the information.
Managing Director
Purchase this report to view the information.
Power of Attorney
Company Performance
Financial values in the chart are available after Perimeter Pharmaceuticals Llc Sp. z o.o. Oddzial W Polsce report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Total operating revenue
14.75%▲
Operating profit (EBIT)
-67.61%▼
EBITDA
-74.49%▼
Net Profit (Loss) for the Period
-74.72%▼
Total assets
138.27%▲
Total equity
145%▲
Return on Equity (ROE)
18.68%▲
Quick Ratio
64.18%▲
Cash Ratio
-1.31%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo